#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	ana	2-11

#Text=Proteases are associated with many signaling biological pathways , and it is has been proven that the number of diseases like cancer , HIV , infectious diseases , and diabetes are treated by inhibiting proteases .
2-1	16-25	Proteases	substance	new	coref	2-35
2-2	26-29	are	_	_	_	_
2-3	30-40	associated	_	_	_	_
2-4	41-45	with	_	_	_	_
2-5	46-50	many	abstract[3]	new[3]	_	_
2-6	51-60	signaling	abstract[3]	new[3]	_	_
2-7	61-71	biological	abstract[3]	new[3]	_	_
2-8	72-80	pathways	abstract[3]	new[3]	_	_
2-9	81-82	,	_	_	_	_
2-10	83-86	and	_	_	_	_
2-11	87-89	it	abstract	giv	_	_
2-12	90-92	is	_	_	_	_
2-13	93-96	has	_	_	_	_
2-14	97-101	been	_	_	_	_
2-15	102-108	proven	_	_	_	_
2-16	109-113	that	_	_	_	_
2-17	114-117	the	abstract[5]	new[5]	_	_
2-18	118-124	number	abstract[5]	new[5]	_	_
2-19	125-127	of	abstract[5]	new[5]	_	_
2-20	128-136	diseases	abstract[5]|abstract[6]	new[5]|new[6]	coref	5-13[30_6]
2-21	137-141	like	abstract[5]|abstract[6]	new[5]|new[6]	_	_
2-22	142-148	cancer	abstract[5]|abstract[6]|abstract	new[5]|new[6]|new	_	_
2-23	149-150	,	abstract[5]|abstract[6]	new[5]|new[6]	_	_
2-24	151-154	HIV	abstract[5]|abstract[6]|abstract	new[5]|new[6]|new	_	_
2-25	155-156	,	abstract[5]|abstract[6]	new[5]|new[6]	_	_
2-26	157-167	infectious	abstract[5]|abstract[6]|abstract[9]	new[5]|new[6]|new[9]	_	_
2-27	168-176	diseases	abstract[5]|abstract[6]|abstract[9]	new[5]|new[6]|new[9]	_	_
2-28	177-178	,	abstract[5]|abstract[6]	new[5]|new[6]	_	_
2-29	179-182	and	abstract[5]|abstract[6]	new[5]|new[6]	_	_
2-30	183-191	diabetes	abstract[5]|abstract[6]|abstract	new[5]|new[6]|new	coref	11-23
2-31	192-195	are	_	_	_	_
2-32	196-203	treated	_	_	_	_
2-33	204-206	by	_	_	_	_
2-34	207-217	inhibiting	_	_	_	_
2-35	218-227	proteases	substance	giv	coref	3-8[14_0]
2-36	228-229	.	_	_	_	_

#Text=Pharmaceutical companies develop commercial drugs to inhibit aspartyl proteases , serine proteases , and cysteine proteases .
3-1	230-244	Pharmaceutical	organization[12]	new[12]	_	_
3-2	245-254	companies	organization[12]	new[12]	_	_
3-3	255-262	develop	_	_	_	_
3-4	263-273	commercial	substance[13]	new[13]	coref	7-24[49_13]
3-5	274-279	drugs	substance[13]	new[13]	_	_
3-6	280-282	to	_	_	_	_
3-7	283-290	inhibit	_	_	_	_
3-8	291-299	aspartyl	substance[14]	giv[14]	_	_
3-9	300-309	proteases	substance[14]	giv[14]	_	_
3-10	310-311	,	substance[14]	giv[14]	_	_
3-11	312-318	serine	substance[14]|animal	giv[14]|new	coref	4-6
3-12	319-328	proteases	substance[14]	giv[14]	_	_
3-13	329-330	,	substance[14]	giv[14]	_	_
3-14	331-334	and	substance[14]	giv[14]	_	_
3-15	335-343	cysteine	substance[14]|abstract	giv[14]|new	_	_
3-16	344-353	proteases	substance[14]	giv[14]	_	_
3-17	354-355	.	_	_	_	_

#Text=Among several protease inhibitors , serine protease inhibitors received significant interest in various applications focused mainly in therapeutics .
4-1	356-361	Among	_	_	_	_
4-2	362-369	several	abstract[18]	new[18]	_	_
4-3	370-378	protease	abstract|abstract[18]	new|new[18]	coref	4-7
4-4	379-389	inhibitors	abstract[18]	new[18]	_	_
4-5	390-391	,	_	_	_	_
4-6	392-398	serine	animal|abstract[21]	giv|new[21]	coref|coref	5-1|5-1[27_21]
4-7	399-407	protease	abstract|abstract[21]	giv|new[21]	coref	5-2
4-8	408-418	inhibitors	abstract[21]	new[21]	_	_
4-9	419-427	received	_	_	_	_
4-10	428-439	significant	abstract[22]	new[22]	_	_
4-11	440-448	interest	abstract[22]	new[22]	_	_
4-12	449-451	in	_	_	_	_
4-13	452-459	various	abstract[23]	new[23]	_	_
4-14	460-472	applications	abstract[23]	new[23]	_	_
4-15	473-480	focused	_	_	_	_
4-16	481-487	mainly	_	_	_	_
4-17	488-490	in	_	_	_	_
4-18	491-503	therapeutics	abstract	new	coref	6-23[43_0]
4-19	504-505	.	_	_	_	_

#Text=Serine protease inhibitors shown in Table 1 , are used in treating diseases like immune-related disorders , inflammatory , respiratory , AIDS , neurodegenerative , and metabolic disorders .
5-1	506-512	Serine	animal|abstract[27]	giv|giv[27]	coref|coref	13-9|19-12[181_27]
5-2	513-521	protease	abstract|abstract[27]	giv|giv[27]	coref	8-9[54_0]
5-3	522-532	inhibitors	abstract[27]	giv[27]	_	_
5-4	533-538	shown	_	_	_	_
5-5	539-541	in	_	_	_	_
5-6	542-547	Table	object	new	coref	7-13[46_0]
5-7	548-549	1	quantity	new	_	_
5-8	550-551	,	_	_	_	_
5-9	552-555	are	_	_	_	_
5-10	556-560	used	_	_	_	_
5-11	561-563	in	_	_	_	_
5-12	564-572	treating	_	_	_	_
5-13	573-581	diseases	abstract[30]	giv[30]	coref	12-31[100_30]
5-14	582-586	like	abstract[30]	giv[30]	_	_
5-15	587-601	immune-related	abstract[30]|abstract[31]	giv[30]|new[31]	_	_
5-16	602-611	disorders	abstract[30]|abstract[31]	giv[30]|new[31]	_	_
5-17	612-613	,	abstract[30]	giv[30]	_	_
5-18	614-626	inflammatory	abstract[30]	giv[30]	_	_
5-19	627-628	,	abstract[30]	giv[30]	_	_
5-20	629-640	respiratory	abstract[30]	giv[30]	_	_
5-21	641-642	,	abstract[30]	giv[30]	_	_
5-22	643-647	AIDS	abstract[30]|abstract	giv[30]|new	_	_
5-23	648-649	,	abstract[30]	giv[30]	_	_
5-24	650-667	neurodegenerative	abstract[30]|abstract	giv[30]|new	_	_
5-25	668-669	,	abstract[30]	giv[30]	_	_
5-26	670-673	and	abstract[30]	giv[30]	_	_
5-27	674-683	metabolic	abstract[30]|abstract|abstract[35]	giv[30]|new|new[35]	coref	7-27[50_35]
5-28	684-693	disorders	abstract[30]|abstract[35]	giv[30]|new[35]	_	_
5-29	694-695	.	_	_	_	_

#Text=Features like therapeutic potential , good binding affinity , low toxicity , and quickly cleavable by proteolytic enzymes , make cyclic peptides potential future therapeutics .
6-1	696-704	Features	abstract[36]	new[36]	_	_
6-2	705-709	like	abstract[36]	new[36]	_	_
6-3	710-721	therapeutic	abstract[36]|abstract[38]	new[36]|new[38]	_	_
6-4	722-731	potential	abstract[36]|abstract[38]	new[36]|new[38]	_	_
6-5	732-733	,	abstract[36]|abstract[38]	new[36]|new[38]	_	_
6-6	734-738	good	abstract[36]|abstract[38]	new[36]|new[38]	_	_
6-7	739-746	binding	abstract[36]|object|abstract[38]	new[36]|new|new[38]	coref	21-10
6-8	747-755	affinity	abstract[36]|abstract[38]	new[36]|new[38]	_	_
6-9	756-757	,	abstract[36]	new[36]	_	_
6-10	758-761	low	abstract[36]|abstract[39]	new[36]|new[39]	coref	17-28[148_39]
6-11	762-770	toxicity	abstract[36]|abstract[39]	new[36]|new[39]	_	_
6-12	771-772	,	abstract[36]	new[36]	_	_
6-13	773-776	and	abstract[36]	new[36]	_	_
6-14	777-784	quickly	abstract[36]|abstract[40]	new[36]|new[40]	_	_
6-15	785-794	cleavable	abstract[36]|abstract[40]	new[36]|new[40]	_	_
6-16	795-797	by	abstract[36]|abstract[40]	new[36]|new[40]	_	_
6-17	798-809	proteolytic	abstract[36]|abstract[40]|object[41]	new[36]|new[40]|new[41]	_	_
6-18	810-817	enzymes	abstract[36]|abstract[40]|object[41]	new[36]|new[40]|new[41]	_	_
6-19	818-819	,	_	_	_	_
6-20	820-824	make	_	_	_	_
6-21	825-831	cyclic	abstract[42]	new[42]	coref	7-1[44_42]
6-22	832-840	peptides	abstract[42]	new[42]	_	_
6-23	841-850	potential	abstract[42]|abstract[43]	new[42]|giv[43]	coref	17-56[0_43]
6-24	851-857	future	abstract[42]|abstract[43]	new[42]|giv[43]	_	_
6-25	858-870	therapeutics	abstract[42]|abstract[43]	new[42]|giv[43]	_	_
6-26	871-872	.	_	_	_	_

#Text=Most of the cyclic peptides approved by the FDA ( shown in Table 2 ) are used in bacterial and fungal infections , oncology drugs , gastrointestinal disorders , and anemia .
7-1	873-877	Most	abstract[44]	giv[44]	coref	8-3[52_44]
7-2	878-880	of	abstract[44]	giv[44]	_	_
7-3	881-884	the	abstract[44]	giv[44]	_	_
7-4	885-891	cyclic	abstract[44]	giv[44]	_	_
7-5	892-900	peptides	abstract[44]	giv[44]	_	_
7-6	901-909	approved	_	_	_	_
7-7	910-912	by	_	_	_	_
7-8	913-916	the	organization[45]	new[45]	_	_
7-9	917-920	FDA	organization[45]	new[45]	_	_
7-10	921-922	(	_	_	_	_
7-11	923-928	shown	_	_	_	_
7-12	929-931	in	_	_	_	_
7-13	932-937	Table	object[46]	giv[46]	_	_
7-14	938-939	2	object[46]	giv[46]	_	_
7-15	940-941	)	_	_	_	_
7-16	942-945	are	_	_	_	_
7-17	946-950	used	_	_	_	_
7-18	951-953	in	_	_	_	_
7-19	954-963	bacterial	substance	new	_	_
7-20	964-967	and	_	_	_	_
7-21	968-974	fungal	object[48]	new[48]	_	_
7-22	975-985	infections	object[48]	new[48]	_	_
7-23	986-987	,	_	_	_	_
7-24	988-996	oncology	substance[49]	giv[49]	_	_
7-25	997-1002	drugs	substance[49]	giv[49]	_	_
7-26	1003-1004	,	_	_	_	_
7-27	1005-1021	gastrointestinal	abstract[50]	giv[50]	_	_
7-28	1022-1031	disorders	abstract[50]	giv[50]	_	_
7-29	1032-1033	,	_	_	_	_
7-30	1034-1037	and	_	_	_	_
7-31	1038-1044	anemia	abstract	new	_	_
7-32	1045-1046	.	_	_	_	_

#Text=Recently , cyclic peptides were proven to inhibit HIV-1 protease ( aspartyl proteases ) and elastase , shedding light onto the use of cyclic peptides as protease inhibitors .
8-1	1047-1055	Recently	_	_	_	_
8-2	1056-1057	,	_	_	_	_
8-3	1058-1064	cyclic	abstract[52]	giv[52]	coref	8-24[58_52]
8-4	1065-1073	peptides	abstract[52]	giv[52]	_	_
8-5	1074-1078	were	_	_	_	_
8-6	1079-1085	proven	_	_	_	_
8-7	1086-1088	to	_	_	_	_
8-8	1089-1096	inhibit	_	_	_	_
8-9	1097-1102	HIV-1	abstract|abstract[54]	new|giv[54]	appos	8-12[55_54]
8-10	1103-1111	protease	abstract[54]	giv[54]	_	_
8-11	1112-1113	(	_	_	_	_
8-12	1114-1122	aspartyl	abstract[55]	giv[55]	coref	8-27[0_55]
8-13	1123-1132	proteases	abstract[55]	giv[55]	_	_
8-14	1133-1134	)	_	_	_	_
8-15	1135-1138	and	_	_	_	_
8-16	1139-1147	elastase	_	_	_	_
8-17	1148-1149	,	_	_	_	_
8-18	1150-1158	shedding	_	_	_	_
8-19	1159-1164	light	abstract	new	_	_
8-20	1165-1169	onto	_	_	_	_
8-21	1170-1173	the	abstract[57]	new[57]	_	_
8-22	1174-1177	use	abstract[57]	new[57]	_	_
8-23	1178-1180	of	abstract[57]	new[57]	_	_
8-24	1181-1187	cyclic	abstract[57]|abstract[58]	new[57]|giv[58]	coref	9-9[64_58]
8-25	1188-1196	peptides	abstract[57]|abstract[58]	new[57]|giv[58]	_	_
8-26	1197-1199	as	abstract[57]|abstract[58]	new[57]|giv[58]	_	_
8-27	1200-1208	protease	abstract[57]|abstract[58]|abstract	new[57]|giv[58]|giv	coref	11-14
8-28	1209-1219	inhibitors	abstract[57]|abstract[58]	new[57]|giv[58]	_	_
8-29	1220-1221	.	_	_	_	_

#Text=Phage display technology , Incretin-based cyclic peptide , cyclic peptides from mRNA display , and split-pool synthesis are some of the tools used to develop cyclic peptide compounds .
9-1	1222-1227	Phage	place|abstract[62]	new|new[62]	_	_
9-2	1228-1235	display	object|abstract[62]	new|new[62]	coref	9-12[66_0]
9-3	1236-1246	technology	abstract[62]	new[62]	_	_
9-4	1247-1248	,	_	_	_	_
9-5	1249-1263	Incretin-based	object[63]	new[63]	coref	9-27[0_63]
9-6	1264-1270	cyclic	object[63]	new[63]	_	_
9-7	1271-1278	peptide	object[63]	new[63]	_	_
9-8	1279-1280	,	_	_	_	_
9-9	1281-1287	cyclic	abstract[64]	giv[64]	coref	11-4[82_64]
9-10	1288-1296	peptides	abstract[64]	giv[64]	_	_
9-11	1297-1301	from	abstract[64]	giv[64]	_	_
9-12	1302-1306	mRNA	abstract[64]|event|object[66]	giv[64]|new|giv[66]	_	_
9-13	1307-1314	display	abstract[64]|object[66]	giv[64]|giv[66]	_	_
9-14	1315-1316	,	_	_	_	_
9-15	1317-1320	and	_	_	_	_
9-16	1321-1331	split-pool	abstract[67]	new[67]	_	_
9-17	1332-1341	synthesis	abstract[67]	new[67]	_	_
9-18	1342-1345	are	_	_	_	_
9-19	1346-1350	some	_	_	_	_
9-20	1351-1353	of	_	_	_	_
9-21	1354-1357	the	abstract[68]	new[68]	_	_
9-22	1358-1363	tools	abstract[68]	new[68]	_	_
9-23	1364-1368	used	_	_	_	_
9-24	1369-1371	to	_	_	_	_
9-25	1372-1379	develop	_	_	_	_
9-26	1380-1386	cyclic	abstract[70]	new[70]	_	_
9-27	1387-1394	peptide	object|abstract[70]	giv|new[70]	coref	10-28
9-28	1395-1404	compounds	abstract[70]	new[70]	_	_
9-29	1405-1406	.	_	_	_	_

#Text=Recently computer-aided drug design technologies like molecular docking simulations are applied to identify , design rationally ( called as de novo developed ) , and develop cyclic peptide ligand as leads to therapeutic drug targets of interest .
10-1	1407-1415	Recently	_	_	_	_
10-2	1416-1430	computer-aided	abstract[73]	new[73]	_	_
10-3	1431-1435	drug	substance|abstract[73]	new|new[73]	coref	10-34
10-4	1436-1442	design	abstract|abstract[73]	new|new[73]	coref	10-15
10-5	1443-1455	technologies	abstract[73]	new[73]	_	_
10-6	1456-1460	like	abstract[73]	new[73]	_	_
10-7	1461-1470	molecular	abstract[73]|abstract[75]	new[73]|new[75]	coref	20-4[188_75]
10-8	1471-1478	docking	abstract[73]|place|abstract[75]	new[73]|new|new[75]	coref	20-5
10-9	1479-1490	simulations	abstract[73]|abstract[75]	new[73]|new[75]	_	_
10-10	1491-1494	are	_	_	_	_
10-11	1495-1502	applied	_	_	_	_
10-12	1503-1505	to	_	_	_	_
10-13	1506-1514	identify	_	_	_	_
10-14	1515-1516	,	_	_	_	_
10-15	1517-1523	design	abstract	giv	_	_
10-16	1524-1534	rationally	_	_	_	_
10-17	1535-1536	(	_	_	_	_
10-18	1537-1543	called	_	_	_	_
10-19	1544-1546	as	_	_	_	_
10-20	1547-1549	de	_	_	_	_
10-21	1550-1554	novo	_	_	_	_
10-22	1555-1564	developed	_	_	_	_
10-23	1565-1566	)	_	_	_	_
10-24	1567-1568	,	_	_	_	_
10-25	1569-1572	and	_	_	_	_
10-26	1573-1580	develop	_	_	_	_
10-27	1581-1587	cyclic	abstract[78]	new[78]	_	_
10-28	1588-1595	peptide	object|abstract[78]	giv|new[78]	coref	15-9
10-29	1596-1602	ligand	abstract[78]	new[78]	_	_
10-30	1603-1605	as	_	_	_	_
10-31	1606-1611	leads	_	_	_	_
10-32	1612-1614	to	_	_	_	_
10-33	1615-1626	therapeutic	abstract[80]	new[80]	_	_
10-34	1627-1631	drug	substance|abstract[80]	giv|new[80]	coref	13-16
10-35	1632-1639	targets	abstract[80]	new[80]	_	_
10-36	1640-1642	of	abstract[80]	new[80]	_	_
10-37	1643-1651	interest	abstract[80]	new[80]	_	_
10-38	1652-1653	.	_	_	_	_

#Text=Till today , cyclic peptides as therapeutics in regulating glucose metabolism by inhibiting proteases have not been reported for the treatment of diabetes mellitus .
11-1	1654-1658	Till	_	_	_	_
11-2	1659-1664	today	time	new	_	_
11-3	1665-1666	,	_	_	_	_
11-4	1667-1673	cyclic	abstract[82]	giv[82]	coref	17-2[142_82]
11-5	1674-1682	peptides	abstract[82]	giv[82]	_	_
11-6	1683-1685	as	abstract[82]	giv[82]	_	_
11-7	1686-1698	therapeutics	abstract[82]	giv[82]	_	_
11-8	1699-1701	in	_	_	_	_
11-9	1702-1712	regulating	_	_	_	_
11-10	1713-1720	glucose	substance|abstract[84]	new|new[84]	coref|coref	13-21|13-20[110_84]
11-11	1721-1731	metabolism	abstract[84]	new[84]	_	_
11-12	1732-1734	by	_	_	_	_
11-13	1735-1745	inhibiting	_	_	_	_
11-14	1746-1755	proteases	substance	giv	coref	17-9[143_0]
11-15	1756-1760	have	_	_	_	_
11-16	1761-1764	not	_	_	_	_
11-17	1765-1769	been	_	_	_	_
11-18	1770-1778	reported	_	_	_	_
11-19	1779-1782	for	_	_	_	_
11-20	1783-1786	the	abstract[86]	new[86]	_	_
11-21	1787-1796	treatment	abstract[86]	new[86]	_	_
11-22	1797-1799	of	abstract[86]	new[86]	_	_
11-23	1800-1808	diabetes	abstract[86]|abstract|abstract[88]	new[86]|giv|new[88]	coref|coref	12-10|12-10[92_88]
11-24	1809-1817	mellitus	abstract[86]|abstract[88]	new[86]|new[88]	_	_
11-25	1818-1819	.	_	_	_	_

#Text=In Mexico , approximately 11.5 million people live with diabetes mellitus ( DM ) , which is the main leading cause of acquired blindness , non-traumatic lower-limb amputations , and chronic kidney failure diseases .
12-1	1820-1822	In	_	_	_	_
12-2	1823-1829	Mexico	place	new	_	_
12-3	1830-1831	,	_	_	_	_
12-4	1832-1845	approximately	quantity[90]	new[90]	_	_
12-5	1846-1850	11.5	quantity[90]	new[90]	_	_
12-6	1851-1858	million	quantity[90]	new[90]	_	_
12-7	1859-1865	people	quantity[90]	new[90]	_	_
12-8	1866-1870	live	_	_	_	_
12-9	1871-1875	with	_	_	_	_
12-10	1876-1884	diabetes	abstract|abstract[92]	giv|giv[92]	coref|coref	13-25|13-25[112_92]
12-11	1885-1893	mellitus	abstract[92]	giv[92]	_	_
12-12	1894-1895	(	_	_	_	_
12-13	1896-1898	DM	abstract	new	_	_
12-14	1899-1900	)	_	_	_	_
12-15	1901-1902	,	_	_	_	_
12-16	1903-1908	which	_	_	_	_
12-17	1909-1911	is	_	_	_	_
12-18	1912-1915	the	abstract[94]	new[94]	_	_
12-19	1916-1920	main	abstract[94]	new[94]	_	_
12-20	1921-1928	leading	abstract[94]	new[94]	_	_
12-21	1929-1934	cause	abstract[94]	new[94]	_	_
12-22	1935-1937	of	abstract[94]	new[94]	_	_
12-23	1938-1946	acquired	abstract[94]|abstract[95]	new[94]|new[95]	_	_
12-24	1947-1956	blindness	abstract[94]|abstract[95]	new[94]|new[95]	_	_
12-25	1957-1958	,	abstract[94]	new[94]	_	_
12-26	1959-1972	non-traumatic	abstract[94]|object[97]	new[94]|new[97]	_	_
12-27	1973-1983	lower-limb	abstract[94]|event|object[97]	new[94]|new|new[97]	_	_
12-28	1984-1995	amputations	abstract[94]|object[97]	new[94]|new[97]	_	_
12-29	1996-1997	,	abstract[94]	new[94]	_	_
12-30	1998-2001	and	abstract[94]	new[94]	_	_
12-31	2002-2009	chronic	abstract[94]|abstract[100]	new[94]|giv[100]	_	_
12-32	2010-2016	kidney	abstract[94]|object|abstract[100]	new[94]|new|giv[100]	_	_
12-33	2017-2024	failure	abstract[94]|abstract|abstract[100]	new[94]|new|giv[100]	_	_
12-34	2025-2033	diseases	abstract[94]|abstract[100]	new[94]|giv[100]	_	_
12-35	2034-2035	.	_	_	_	_

#Text=Human dipeptidyl peptidase-4 ( DPP4 ) is a serine protease , well known FDA-approved therapeutic drug target for regulating blood glucose metabolism and treating diabetes mellitus .
13-1	2036-2041	Human	object[102]	new[102]	coref	13-8[105_102]
13-2	2042-2052	dipeptidyl	abstract|object[102]	new|new[102]	coref	14-19
13-3	2053-2064	peptidase-4	object[102]	new[102]	_	_
13-4	2065-2066	(	_	_	_	_
13-5	2067-2071	DPP4	object	new	coref	14-22
13-6	2072-2073	)	_	_	_	_
13-7	2074-2076	is	_	_	_	_
13-8	2077-2078	a	object[105]	giv[105]	coref	14-18[120_105]
13-9	2079-2085	serine	animal|object[105]	giv|giv[105]	coref	16-7
13-10	2086-2094	protease	object[105]	giv[105]	_	_
13-11	2095-2096	,	object[105]	giv[105]	_	_
13-12	2097-2101	well	object[105]	giv[105]	_	_
13-13	2102-2107	known	object[105]	giv[105]	_	_
13-14	2108-2120	FDA-approved	object[105]|abstract[107]	giv[105]|new[107]	_	_
13-15	2121-2132	therapeutic	object[105]|abstract[107]	giv[105]|new[107]	_	_
13-16	2133-2137	drug	object[105]|substance|abstract[107]	giv[105]|giv|new[107]	_	_
13-17	2138-2144	target	object[105]|abstract[107]	giv[105]|new[107]	_	_
13-18	2145-2148	for	_	_	_	_
13-19	2149-2159	regulating	_	_	_	_
13-20	2160-2165	blood	substance|abstract[110]	new|giv[110]	_	_
13-21	2166-2173	glucose	substance|abstract[110]	giv|giv[110]	coref	15-27
13-22	2174-2184	metabolism	abstract[110]	giv[110]	_	_
13-23	2185-2188	and	_	_	_	_
13-24	2189-2197	treating	_	_	_	_
13-25	2198-2206	diabetes	abstract|abstract[112]	giv|giv[112]	coref|coref	17-65|17-65[162_112]
13-26	2207-2215	mellitus	abstract[112]	giv[112]	_	_
13-27	2216-2217	.	_	_	_	_

#Text=Sitagliptin , Vildagliptin , Anagliptin , Saxagliptin , and Alogliptin are the main clinically used chemicals for human dipeptidyl peptidase-4 ( DPP4 ) inhibition despite their side effects as pancreatitis , nausea , and anemia .
14-1	2218-2229	Sitagliptin	substance	new	_	_
14-2	2230-2231	,	_	_	_	_
14-3	2232-2244	Vildagliptin	substance	new	_	_
14-4	2245-2246	,	_	_	_	_
14-5	2247-2257	Anagliptin	substance	new	_	_
14-6	2258-2259	,	_	_	_	_
14-7	2260-2271	Saxagliptin	substance	new	_	_
14-8	2272-2273	,	_	_	_	_
14-9	2274-2277	and	_	_	_	_
14-10	2278-2288	Alogliptin	substance	new	coref	14-12[118_0]
14-11	2289-2292	are	_	_	_	_
14-12	2293-2296	the	substance[118]	giv[118]	coref	17-24[147_118]
14-13	2297-2301	main	substance[118]	giv[118]	_	_
14-14	2302-2312	clinically	substance[118]	giv[118]	_	_
14-15	2313-2317	used	substance[118]	giv[118]	_	_
14-16	2318-2327	chemicals	substance[118]	giv[118]	_	_
14-17	2328-2331	for	substance[118]	giv[118]	_	_
14-18	2332-2337	human	substance[118]|substance[120]	giv[118]|giv[120]	coref	16-6[140_120]
14-19	2338-2348	dipeptidyl	substance[118]|abstract|substance[120]	giv[118]|giv|giv[120]	coref	16-10
14-20	2349-2360	peptidase-4	substance[118]|substance[120]	giv[118]|giv[120]	_	_
14-21	2361-2362	(	substance[118]	giv[118]	_	_
14-22	2363-2367	DPP4	substance[118]|abstract	giv[118]|giv	coref	16-13
14-23	2368-2369	)	substance[118]	giv[118]	_	_
14-24	2370-2380	inhibition	substance[118]|abstract[122]	giv[118]|new[122]	ana	15-1[0_122]
14-25	2381-2388	despite	substance[118]|abstract[122]	giv[118]|new[122]	_	_
14-26	2389-2394	their	substance[118]|abstract[122]|abstract[124]	giv[118]|new[122]|new[124]	_	_
14-27	2395-2399	side	substance[118]|abstract[122]|abstract|abstract[124]	giv[118]|new[122]|new|new[124]	_	_
14-28	2400-2407	effects	substance[118]|abstract[122]|abstract[124]	giv[118]|new[122]|new[124]	_	_
14-29	2408-2410	as	substance[118]|abstract[122]|abstract[124]	giv[118]|new[122]|new[124]	_	_
14-30	2411-2423	pancreatitis	substance[118]|abstract[122]|abstract[124]	giv[118]|new[122]|new[124]	_	_
14-31	2424-2425	,	substance[118]|abstract[122]|abstract[124]	giv[118]|new[122]|new[124]	_	_
14-32	2426-2432	nausea	substance[118]|abstract[122]|abstract[124]	giv[118]|new[122]|new[124]	_	_
14-33	2433-2434	,	substance[118]|abstract[122]|abstract[124]	giv[118]|new[122]|new[124]	_	_
14-34	2435-2438	and	substance[118]|abstract[122]|abstract[124]	giv[118]|new[122]|new[124]	_	_
14-35	2439-2445	anemia	substance[118]|abstract[122]|abstract[124]	giv[118]|new[122]|new[124]	_	_
14-36	2446-2447	.	_	_	_	_

#Text=It is well known that incretin hormones glucagon-like peptide 1 ( GLP-1 ) and glucose-dependent insulinotropic polypeptide ( GIP ) are responsible for insulin release and glucose regulation .
15-1	2448-2450	It	abstract	giv	coref	18-30
15-2	2451-2453	is	_	_	_	_
15-3	2454-2458	well	_	_	_	_
15-4	2459-2464	known	_	_	_	_
15-5	2465-2469	that	_	_	_	_
15-6	2470-2478	incretin	abstract|substance[127]	new|new[127]	coref	16-1[137_127]
15-7	2479-2487	hormones	substance[127]	new[127]	_	_
15-8	2488-2501	glucagon-like	substance[127]	new[127]	_	_
15-9	2502-2509	peptide	object	giv	_	_
15-10	2510-2511	1	_	_	_	_
15-11	2512-2513	(	_	_	_	_
15-12	2514-2519	GLP-1	time	new	_	_
15-13	2520-2521	)	_	_	_	_
15-14	2522-2525	and	_	_	_	_
15-15	2526-2543	glucose-dependent	abstract[131]	new[131]	appos	15-19[0_131]
15-16	2544-2558	insulinotropic	abstract|abstract[131]	new|new[131]	_	_
15-17	2559-2570	polypeptide	abstract[131]	new[131]	_	_
15-18	2571-2572	(	_	_	_	_
15-19	2573-2576	GIP	abstract	giv	_	_
15-20	2577-2578	)	_	_	_	_
15-21	2579-2582	are	_	_	_	_
15-22	2583-2594	responsible	_	_	_	_
15-23	2595-2598	for	_	_	_	_
15-24	2599-2606	insulin	abstract|event[134]	new|new[134]	_	_
15-25	2607-2614	release	event[134]	new[134]	_	_
15-26	2615-2618	and	_	_	_	_
15-27	2619-2626	glucose	substance|abstract[136]	giv|new[136]	_	_
15-28	2627-2637	regulation	abstract[136]	new[136]	_	_
15-29	2638-2639	.	_	_	_	_

#Text=These hormones are inactivated by a serine protease human dipeptidyl peptidase-4 ( DPP4 ) .
16-1	2640-2645	These	substance[137]	giv[137]	_	_
16-2	2646-2654	hormones	substance[137]	giv[137]	_	_
16-3	2655-2658	are	_	_	_	_
16-4	2659-2670	inactivated	_	_	_	_
16-5	2671-2673	by	_	_	_	_
16-6	2674-2675	a	substance[140]	giv[140]	coref	17-60[0_140]
16-7	2676-2682	serine	animal|substance[140]	giv|giv[140]	coref	17-59
16-8	2683-2691	protease	substance[140]	giv[140]	_	_
16-9	2692-2697	human	substance[140]	giv[140]	_	_
16-10	2698-2708	dipeptidyl	abstract|substance[140]	giv|giv[140]	_	_
16-11	2709-2720	peptidase-4	substance[140]	giv[140]	_	_
16-12	2721-2722	(	_	_	_	_
16-13	2723-2727	DPP4	object	giv	coref	17-59[159_0]
16-14	2728-2729	)	_	_	_	_
16-15	2730-2731	.	_	_	_	_

#Text=Since natural cyclic peptides are proven to inhibit various proteases , and to consider the beneficial aspects of cyclic peptides in comparison to small chemicals , like less toxicity , no accumulation in organs , and rapid degradation of peptides , we hypothesized that cyclic peptides from natural sources could be an alternative source of therapeutics to inhibit serine protease DPP4 for treatment of diabetes mellitus .
17-1	2732-2737	Since	_	_	_	_
17-2	2738-2745	natural	abstract[142]	giv[142]	coref	17-19[145_142]
17-3	2746-2752	cyclic	abstract[142]	giv[142]	_	_
17-4	2753-2761	peptides	abstract[142]	giv[142]	_	_
17-5	2762-2765	are	_	_	_	_
17-6	2766-2772	proven	_	_	_	_
17-7	2773-2775	to	_	_	_	_
17-8	2776-2783	inhibit	_	_	_	_
17-9	2784-2791	various	substance[143]	giv[143]	_	_
17-10	2792-2801	proteases	substance[143]	giv[143]	_	_
17-11	2802-2803	,	_	_	_	_
17-12	2804-2807	and	_	_	_	_
17-13	2808-2810	to	_	_	_	_
17-14	2811-2819	consider	_	_	_	_
17-15	2820-2823	the	abstract[144]	new[144]	_	_
17-16	2824-2834	beneficial	abstract[144]	new[144]	_	_
17-17	2835-2842	aspects	abstract[144]	new[144]	_	_
17-18	2843-2845	of	abstract[144]	new[144]	_	_
17-19	2846-2852	cyclic	abstract[144]|abstract[145]	new[144]|giv[145]	coref	17-45[153_145]
17-20	2853-2861	peptides	abstract[144]|abstract[145]	new[144]|giv[145]	_	_
17-21	2862-2864	in	abstract[144]|abstract[145]	new[144]|giv[145]	_	_
17-22	2865-2875	comparison	abstract[144]|abstract[145]|abstract[146]	new[144]|giv[145]|new[146]	_	_
17-23	2876-2878	to	abstract[144]|abstract[145]|abstract[146]	new[144]|giv[145]|new[146]	_	_
17-24	2879-2884	small	abstract[144]|abstract[145]|abstract[146]|substance[147]	new[144]|giv[145]|new[146]|giv[147]	_	_
17-25	2885-2894	chemicals	abstract[144]|abstract[145]|abstract[146]|substance[147]	new[144]|giv[145]|new[146]|giv[147]	_	_
17-26	2895-2896	,	abstract[144]|abstract[145]|abstract[146]|substance[147]	new[144]|giv[145]|new[146]|giv[147]	_	_
17-27	2897-2901	like	abstract[144]|abstract[145]|abstract[146]|substance[147]	new[144]|giv[145]|new[146]|giv[147]	_	_
17-28	2902-2906	less	abstract[144]|abstract[145]|abstract[146]|substance[147]|abstract[148]	new[144]|giv[145]|new[146]|giv[147]|giv[148]	_	_
17-29	2907-2915	toxicity	abstract[144]|abstract[145]|abstract[146]|substance[147]|abstract[148]	new[144]|giv[145]|new[146]|giv[147]|giv[148]	_	_
17-30	2916-2917	,	abstract[144]|abstract[145]|abstract[146]|substance[147]	new[144]|giv[145]|new[146]|giv[147]	_	_
17-31	2918-2920	no	abstract[144]|abstract[145]|abstract[146]|substance[147]|abstract[149]	new[144]|giv[145]|new[146]|giv[147]|new[149]	_	_
17-32	2921-2933	accumulation	abstract[144]|abstract[145]|abstract[146]|substance[147]|abstract[149]	new[144]|giv[145]|new[146]|giv[147]|new[149]	_	_
17-33	2934-2936	in	abstract[144]|abstract[145]|abstract[146]|substance[147]|abstract[149]	new[144]|giv[145]|new[146]|giv[147]|new[149]	_	_
17-34	2937-2943	organs	abstract[144]|abstract[145]|abstract[146]|substance[147]|abstract[149]|object	new[144]|giv[145]|new[146]|giv[147]|new[149]|new	_	_
17-35	2944-2945	,	abstract[144]|abstract[145]|abstract[146]|substance[147]	new[144]|giv[145]|new[146]|giv[147]	_	_
17-36	2946-2949	and	abstract[144]|abstract[145]|abstract[146]|substance[147]	new[144]|giv[145]|new[146]|giv[147]	_	_
17-37	2950-2955	rapid	abstract[144]|abstract[145]|abstract[146]|substance[147]|abstract[151]	new[144]|giv[145]|new[146]|giv[147]|new[151]	_	_
17-38	2956-2967	degradation	abstract[144]|abstract[145]|abstract[146]|substance[147]|abstract[151]	new[144]|giv[145]|new[146]|giv[147]|new[151]	_	_
17-39	2968-2970	of	abstract[144]|abstract[145]|abstract[146]|substance[147]|abstract[151]	new[144]|giv[145]|new[146]|giv[147]|new[151]	_	_
17-40	2971-2979	peptides	abstract[144]|abstract[145]|abstract[146]|substance[147]|abstract[151]	new[144]|giv[145]|new[146]|giv[147]|new[151]	_	_
17-41	2980-2981	,	_	_	_	_
17-42	2982-2984	we	person	acc	ana	18-21
17-43	2985-2997	hypothesized	_	_	_	_
17-44	2998-3002	that	_	_	_	_
17-45	3003-3009	cyclic	abstract[153]	giv[153]	coref	17-52[155_153]
17-46	3010-3018	peptides	abstract[153]	giv[153]	_	_
17-47	3019-3023	from	abstract[153]	giv[153]	_	_
17-48	3024-3031	natural	abstract[153]|abstract[154]	giv[153]|new[154]	_	_
17-49	3032-3039	sources	abstract[153]|abstract[154]	giv[153]|new[154]	_	_
17-50	3040-3045	could	_	_	_	_
17-51	3046-3048	be	_	_	_	_
17-52	3049-3051	an	abstract[155]	giv[155]	coref	18-2[163_155]
17-53	3052-3063	alternative	abstract[155]	giv[155]	_	_
17-54	3064-3070	source	abstract[155]	giv[155]	_	_
17-55	3071-3073	of	abstract[155]	giv[155]	_	_
17-56	3074-3086	therapeutics	abstract[155]|abstract	giv[155]|giv	_	_
17-57	3087-3089	to	_	_	_	_
17-58	3090-3097	inhibit	_	_	_	_
17-59	3098-3104	serine	animal|object[159]	giv|giv[159]	coref|coref	18-28|18-36[0_159]
17-60	3105-3113	protease	abstract|object[159]	giv|giv[159]	coref	18-29
17-61	3114-3118	DPP4	object[159]	giv[159]	_	_
17-62	3119-3122	for	_	_	_	_
17-63	3123-3132	treatment	abstract[160]	new[160]	_	_
17-64	3133-3135	of	abstract[160]	new[160]	_	_
17-65	3136-3144	diabetes	abstract[160]|abstract|abstract[162]	new[160]|giv|giv[162]	_	_
17-66	3145-3153	mellitus	abstract[160]|abstract[162]	new[160]|giv[162]	_	_
17-67	3154-3155	.	_	_	_	_

#Text=Among various naturally occurring cyclic peptides , oxytocin ( natural cyclic peptide ) was chosen in this study to prove our hypothesis that , cyclic peptides possess serine protease inhibition activity , and specifically inhibit DPP4 .
18-1	3156-3161	Among	_	_	_	_
18-2	3162-3169	various	abstract[163]	giv[163]	coref	18-25[169_163]
18-3	3170-3179	naturally	abstract[163]	giv[163]	_	_
18-4	3180-3189	occurring	abstract[163]	giv[163]	_	_
18-5	3190-3196	cyclic	abstract[163]	giv[163]	_	_
18-6	3197-3205	peptides	abstract[163]	giv[163]	_	_
18-7	3206-3207	,	_	_	_	_
18-8	3208-3216	oxytocin	substance	new	appos	18-10[165_0]
18-9	3217-3218	(	_	_	_	_
18-10	3219-3226	natural	substance[165]	giv[165]	coref	19-24[184_165]
18-11	3227-3233	cyclic	substance[165]	giv[165]	_	_
18-12	3234-3241	peptide	substance[165]	giv[165]	_	_
18-13	3242-3243	)	_	_	_	_
18-14	3244-3247	was	_	_	_	_
18-15	3248-3254	chosen	_	_	_	_
18-16	3255-3257	in	_	_	_	_
18-17	3258-3262	this	event[166]	new[166]	_	_
18-18	3263-3268	study	event[166]	new[166]	_	_
18-19	3269-3271	to	_	_	_	_
18-20	3272-3277	prove	_	_	_	_
18-21	3278-3281	our	person|abstract[168]	giv|new[168]	ana|coref	19-3|19-3[176_168]
18-22	3282-3292	hypothesis	abstract[168]	new[168]	_	_
18-23	3293-3297	that	_	_	_	_
18-24	3298-3299	,	_	_	_	_
18-25	3300-3306	cyclic	abstract[169]	giv[169]	_	_
18-26	3307-3315	peptides	abstract[169]	giv[169]	_	_
18-27	3316-3323	possess	_	_	_	_
18-28	3324-3330	serine	animal|abstract[173]	giv|new[173]	coref	19-6[0_173]
18-29	3331-3339	protease	abstract|abstract[173]	giv|new[173]	_	_
18-30	3340-3350	inhibition	abstract|abstract[173]	giv|new[173]	coref	19-27[186_0]
18-31	3351-3359	activity	abstract[173]	new[173]	_	_
18-32	3360-3361	,	_	_	_	_
18-33	3362-3365	and	_	_	_	_
18-34	3366-3378	specifically	_	_	_	_
18-35	3379-3386	inhibit	_	_	_	_
18-36	3387-3391	DPP4	abstract	giv	coref	19-12
18-37	3392-3393	.	_	_	_	_

#Text=To demonstrate our hypothesis , activity atlas and field-based models of DPP4 inhibitors from natural origin were utilized to elucidate molecular insights of oxytocin peptide into DPP4 inhibition .
19-1	3394-3396	To	_	_	_	_
19-2	3397-3408	demonstrate	_	_	_	_
19-3	3409-3412	our	person|abstract[176]	giv|giv[176]	_	_
19-4	3413-3423	hypothesis	abstract[176]	giv[176]	_	_
19-5	3424-3425	,	_	_	_	_
19-6	3426-3434	activity	abstract|abstract[178]	giv|new[178]	coref	20-19[191_0]
19-7	3435-3440	atlas	abstract[178]	new[178]	_	_
19-8	3441-3444	and	_	_	_	_
19-9	3445-3456	field-based	abstract[179]	new[179]	_	_
19-10	3457-3463	models	abstract[179]	new[179]	_	_
19-11	3464-3466	of	abstract[179]	new[179]	_	_
19-12	3467-3471	DPP4	abstract[179]|abstract|abstract[181]	new[179]|giv|giv[181]	coref	19-27
19-13	3472-3482	inhibitors	abstract[179]|abstract[181]	new[179]|giv[181]	_	_
19-14	3483-3487	from	abstract[179]|abstract[181]	new[179]|giv[181]	_	_
19-15	3488-3495	natural	abstract[179]|abstract[181]|abstract[182]	new[179]|giv[181]|new[182]	_	_
19-16	3496-3502	origin	abstract[179]|abstract[181]|abstract[182]	new[179]|giv[181]|new[182]	_	_
19-17	3503-3507	were	_	_	_	_
19-18	3508-3516	utilized	_	_	_	_
19-19	3517-3519	to	_	_	_	_
19-20	3520-3529	elucidate	_	_	_	_
19-21	3530-3539	molecular	abstract[183]	new[183]	coref	21-27[203_183]
19-22	3540-3548	insights	abstract[183]	new[183]	_	_
19-23	3549-3551	of	abstract[183]	new[183]	_	_
19-24	3552-3560	oxytocin	abstract[183]|object[184]	new[183]|giv[184]	coref	21-13[0_184]
19-25	3561-3568	peptide	abstract[183]|object[184]	new[183]|giv[184]	_	_
19-26	3569-3573	into	_	_	_	_
19-27	3574-3578	DPP4	abstract|abstract[186]	giv|giv[186]	coref	21-37
19-28	3579-3589	inhibition	abstract[186]	giv[186]	_	_
19-29	3590-3591	.	_	_	_	_

#Text=In addition , molecular docking simulations were used to understand the binding poses and interacting residues responsible for inhibitory activity .
20-1	3592-3594	In	_	_	_	_
20-2	3595-3603	addition	_	_	_	_
20-3	3604-3605	,	_	_	_	_
20-4	3606-3615	molecular	event[188]	giv[188]	_	_
20-5	3616-3623	docking	place|event[188]	giv|giv[188]	_	_
20-6	3624-3635	simulations	event[188]	giv[188]	_	_
20-7	3636-3640	were	_	_	_	_
20-8	3641-3645	used	_	_	_	_
20-9	3646-3648	to	_	_	_	_
20-10	3649-3659	understand	_	_	_	_
20-11	3660-3663	the	abstract[189]	new[189]	_	_
20-12	3664-3671	binding	abstract[189]	new[189]	_	_
20-13	3672-3677	poses	abstract[189]	new[189]	_	_
20-14	3678-3681	and	_	_	_	_
20-15	3682-3693	interacting	abstract[190]	new[190]	_	_
20-16	3694-3702	residues	abstract[190]	new[190]	_	_
20-17	3703-3714	responsible	abstract[190]	new[190]	_	_
20-18	3715-3718	for	_	_	_	_
20-19	3719-3729	inhibitory	abstract[191]	giv[191]	_	_
20-20	3730-3738	activity	abstract[191]	giv[191]	_	_
20-21	3739-3740	.	_	_	_	_

#Text=Also , the stability of water molecules at the binding site of oxytocin was studied using 3D reference interaction site model ( 3D-RISM ) to gain deep insights into the binding of the cyclic peptide at DPP4 druggable region .
21-1	3741-3745	Also	_	_	_	_
21-2	3746-3747	,	_	_	_	_
21-3	3748-3751	the	abstract[192]	new[192]	_	_
21-4	3752-3761	stability	abstract[192]	new[192]	_	_
21-5	3762-3764	of	abstract[192]	new[192]	_	_
21-6	3765-3770	water	abstract[192]|substance|substance[194]	new[192]|new|new[194]	_	_
21-7	3771-3780	molecules	abstract[192]|substance[194]	new[192]|new[194]	_	_
21-8	3781-3783	at	abstract[192]|substance[194]	new[192]|new[194]	_	_
21-9	3784-3787	the	abstract[192]|substance[194]|object[196]	new[192]|new[194]|new[196]	coref	21-20[0_196]
21-10	3788-3795	binding	abstract[192]|substance[194]|object|object[196]	new[192]|new[194]|giv|new[196]	coref	21-30[204_0]
21-11	3796-3800	site	abstract[192]|substance[194]|object[196]	new[192]|new[194]|new[196]	_	_
21-12	3801-3803	of	abstract[192]|substance[194]|object[196]	new[192]|new[194]|new[196]	_	_
21-13	3804-3812	oxytocin	abstract[192]|substance[194]|object[196]|substance	new[192]|new[194]|new[196]|giv	coref	21-33[205_0]
21-14	3813-3816	was	_	_	_	_
21-15	3817-3824	studied	_	_	_	_
21-16	3825-3830	using	_	_	_	_
21-17	3831-3833	3D	abstract[201]	new[201]	appos	21-23[0_201]
21-18	3834-3843	reference	person|abstract[201]	new|new[201]	_	_
21-19	3844-3855	interaction	abstract|abstract[201]	new|new[201]	_	_
21-20	3856-3860	site	object|abstract[201]	giv|new[201]	_	_
21-21	3861-3866	model	abstract[201]	new[201]	_	_
21-22	3867-3868	(	_	_	_	_
21-23	3869-3876	3D-RISM	abstract	giv	_	_
21-24	3877-3878	)	_	_	_	_
21-25	3879-3881	to	_	_	_	_
21-26	3882-3886	gain	_	_	_	_
21-27	3887-3891	deep	abstract[203]	giv[203]	_	_
21-28	3892-3900	insights	abstract[203]	giv[203]	_	_
21-29	3901-3905	into	abstract[203]	giv[203]	_	_
21-30	3906-3909	the	abstract[203]|object[204]	giv[203]|giv[204]	_	_
21-31	3910-3917	binding	abstract[203]|object[204]	giv[203]|giv[204]	_	_
21-32	3918-3920	of	abstract[203]|object[204]	giv[203]|giv[204]	_	_
21-33	3921-3924	the	abstract[203]|object[204]|object[205]	giv[203]|giv[204]|giv[205]	coref	22-13[211_205]
21-34	3925-3931	cyclic	abstract[203]|object[204]|object[205]	giv[203]|giv[204]|giv[205]	_	_
21-35	3932-3939	peptide	abstract[203]|object[204]|object[205]	giv[203]|giv[204]|giv[205]	_	_
21-36	3940-3942	at	abstract[203]|object[204]|object[205]	giv[203]|giv[204]|giv[205]	_	_
21-37	3943-3947	DPP4	abstract[203]|object[204]|object[205]|place|place[207]	giv[203]|giv[204]|giv[205]|giv|new[207]	_	_
21-38	3948-3957	druggable	abstract[203]|object[204]|object[205]|place[207]	giv[203]|giv[204]|giv[205]|new[207]	_	_
21-39	3958-3964	region	abstract[203]|object[204]|object[205]|place[207]	giv[203]|giv[204]|giv[205]|new[207]	_	_
21-40	3965-3966	.	_	_	_	_

#Text=Finally , fluorescence assay was used to demonstrate the potential role of oxytocin as a DPP4 inhibitor experimentally .
22-1	3967-3974	Finally	_	_	_	_
22-2	3975-3976	,	_	_	_	_
22-3	3977-3989	fluorescence	abstract|abstract[209]	new|new[209]	_	_
22-4	3990-3995	assay	abstract[209]	new[209]	_	_
22-5	3996-3999	was	_	_	_	_
22-6	4000-4004	used	_	_	_	_
22-7	4005-4007	to	_	_	_	_
22-8	4008-4019	demonstrate	_	_	_	_
22-9	4020-4023	the	abstract[210]	new[210]	_	_
22-10	4024-4033	potential	abstract[210]	new[210]	_	_
22-11	4034-4038	role	abstract[210]	new[210]	_	_
22-12	4039-4041	of	abstract[210]	new[210]	_	_
22-13	4042-4050	oxytocin	abstract[210]|substance[211]	new[210]|giv[211]	_	_
22-14	4051-4053	as	abstract[210]|substance[211]	new[210]|giv[211]	_	_
22-15	4054-4055	a	abstract[210]|substance[211]	new[210]|giv[211]	_	_
22-16	4056-4060	DPP4	abstract[210]|substance[211]	new[210]|giv[211]	_	_
22-17	4061-4070	inhibitor	abstract[210]|substance[211]	new[210]|giv[211]	_	_
22-18	4071-4085	experimentally	abstract[210]|substance[211]	new[210]|giv[211]	_	_
22-19	4086-4087	.	_	_	_	_
